New Blood Protein Signature Could Predict and Prevent Lung Cancer
Researchers have identified a specific set of 14 proteins in the blood that can predict the development of lung cancer more than five years before a clinical diagnosis. By applying machine learning to 48,000 blood samples, a team of over 80 international investigators found that this protein “signature” offers a more accurate risk assessment than current screening models. The findings, published in the journal Cell, suggest that targeting the underlying inflammation linked to these proteins could potentially prevent the disease from developing.
The researchers validated their 14-protein signature across eight global datasets, including a study from Taiwan that specifically focused on individuals who had never smoked, highlighting the potential for broader application beyond traditional risk groups.
Why Inflammation Matters in Lung Cancer
The study suggests that lung cancer development is driven by a combination of genetic mutations and chronic inflammation, often triggered by factors like smoking and air pollution. Charles Swanton, the study’s lead author and director of the Francis Crick Institute, notes that these proteins are also elevated in patients who later develop chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. This shared inflammatory pathway indicates that the biological environment for these conditions is established well before a tumor appears.
The shift toward targeting inflammation represents a significant departure from traditional reactive treatments. By treating the “soil” in which cancer grows—the inflammatory environment—rather than just the cancer itself, medicine may finally move toward a preventative model similar to how statins are used to manage cardiovascular risk. However, the trade-off remains the potential toxicity of anti-inflammatory drugs, which can increase risks like sepsis.
The Path Toward Clinical Prevention
A possible next step involves conducting randomized clinical trials to determine if anti-inflammatory drugs, such as canakinumab, can safely prevent lung cancer. In a retrospective review of 4,650 patients, those with high levels of the 14-protein signature who received canakinumab saw their risk of lung cancer reduced by nearly half. Because the drug can carry significant side effects, experts like Peter Mazzone of the Cleveland Clinic caution that future research must ensure the therapy is not more toxic than the risk it aims to mitigate.
Improving Early Detection
Beyond prevention, this protein signature may refine how clinicians identify patients for low-dose computed tomography (CT) scans. Currently, many eligible patients do not undergo recommended screenings, and the existing criteria often overlook individuals who have never smoked. Using a blood test to identify high-risk individuals could improve screening access and help doctors capture the disease in its earliest, most treatable stages.
Frequently Asked Questions
How accurate is the new protein test compared to current methods?
When combined with data on age, smoking history, and prior lung disease, the 14-protein signature predicted lung cancer development with higher accuracy than the best risk assessment models currently in use.
Is the drug canakinumab ready for use as a cancer preventative?
No. While the study showed a reduction in lung cancer incidence among patients who took the drug during a trial for heart disease, researchers emphasize that a randomized clinical trial specifically designed to test canakinumab for cancer prevention is required before it can be recommended for patient use.
What are the main risks associated with this potential treatment?
According to medical experts, canakinumab can lead to significant side effects, including an increased risk of infection and sepsis, which currently limits its application for healthy individuals.
How might the ability to predict lung cancer years in advance change the way you approach your own long-term health screenings?